SAN ANTONIO, May 17, 2016 /PRNewswire/ -- Mission Pharmacal Company today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for over-the-counter liquid Potassium Iodide Oral Solution USP. The solution is a ready to use thyroid blocking medication that can be used by all ages in the event of a nuclear emergency. Although potassium iodide tablets are available, the FDA recommends a liquid oral solution for infants and small children because it allows for accurate and precise dosing.
Potassium iodide works by saturating the thyroid, thereby preventing radioactive iodine from entering the organ. The sooner a person takes potassium iodide following exposure, the more effective the drug will be in preventing thyroid cancer, a leading health concern following nuclear radiation. Infants, children, and pregnant and nursing females are the most vulnerable to radiation poisoning.
"Mission Pharmacal has a long history of dedication to the health and wellbeing of children. We understand the importance of providing a liquid form of potassium iodide that can help protect our nation's most precious resource, our children, who are at greatest risk in the event of a nuclear emergency," says Terry Herring, President of Commercial Operations for Mission Pharmacal. "The FDA's approval of the ANDA for Potassium Iodide Oral Solution is yet another milestone for Mission Pharmacal in our long history and dedication to protecting young lives."
Mission Pharmacal Company plans to begin manufacturing its Potassium Iodide Oral Solution immediately.
To learn more about Mission Pharmacal Company and its high-quality products for the pediatric population and other core areas, please visit missionpharmacal.com. More information about the company's Potassium Iodide Oral Solution can be found at liquidki.com.
About Mission Pharmacal Company
Mission Pharmacal Company is a privately held pharmaceutical company based in San Antonio, Texas. For nearly seven decades, the company has been improving the lives of people through every stage of life by identifying unmet healthcare needs and delivering innovative, high-quality prescription, over-the-counter, and dietary supplement products to meet these needs using only the purest ingredients and FDA-approved methods of manufacturing. Mission is recognized as a pioneer and leader in the therapeutic areas of women's health and urology and also offers leading products through its pediatric, dermatology, primary care, and long-term care service lines. Using an innovative business model, Mission has created wholly-owned subsidiaries, BioComp Pharma®, Inc., a generic drug marketer; Alamo Pharma Services®, Inc., a specialized contract sales organization; ProSolus®, Inc., a transdermal drug developer and manufacturer; and BexR Logistics™ LLC, a logistics and fulfillment arm, to diversify its offerings and build forward-thinking partnerships with other pharmaceutical and biotech companies. Mission Pharmacal is a proud national supporter of the March of Dimes Foundation®, whose mission is to improve the health of babies by preventing birth defects, premature birth, and infant mortality. To learn more, please visit missionpharmacal.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mission-pharmacal-receives-fda-approval-for-liquid-potassium-iodide-oral-solution-for-nuclear-emergency-management-300270047.html
SOURCE Mission Pharmacal Company